Across TCGA pan-cancer cohorts, ATAD3A Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATAD3A data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATAD3A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATAD3A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, PRAD, and ESCA are the cancer types where ATAD3A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.245	0.835	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.301	0.707	.006	6	view →
UCEC	DFS	Median	All	0.962	0.830	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ATAD3A tumor-vs-normal RNA expression · all ATAD3A data types